Tensive
A Milan medtech advancing REGENERA, a device designed to be gradually replaced by the patient's own tissue, towards regulatory approval.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Wonderful, Tensive, Backbone — $550M for enterprise AI, €20M for breast reconstruction and €4M for food safety — Daily News September 3, 2026
Listen to the episodeAbout Tensive
Tensive develops REGENERA, branded SOFTAG in the United States, a bioresorbable polymeric scaffold intended for breast reconstruction after lumpectomy. The device is inserted into the cavity left by tumour removal and is designed to support the patient's tissue as the material is gradually absorbed. Founded in Milan in 2012 as a Fondazione Filarete spin-off, the company closed a €14 million Series A in 2025 and signed up to €20 million in convertible financing with the European Investment Bank in September 2026. The proceeds will fund clinical studies, CE marking, industrialisation and launch readiness. REGENERA remains under development: the reported results are promising, but approval, clinical adoption and performance at scale have not yet been established.
The Story
Founded in 2012 by Irini Gerges, Margherita Tamplenizza, Federico Martello and Alessandro Tocchio around a biomaterials platform developed in Milan.
How Tensive works
Business Model
A B2B medical-device model serving hospitals, oncology centres and surgeons.
Revenue Model
Future medical-device sales and potential distribution or licensing agreements; pricing and commercial terms have not been disclosed.
Products & Services
Key Products
- REGENERA
- SOFTAG
Core Use Cases
- Breast reconstruction after lumpectomy
- Support for tissue regeneration
- Surgical-site marking for radiotherapy and follow-up
Market & Clients
Key Customers
Hospitals, oncology centres, breast surgeons and healthcare providers, subject to regulatory approval.
Geographic Presence
How Tensive competes
Competitive Advantages
- A one-step procedure during lumpectomy
- Bioresorbable material designed to be replaced by the patient's tissue
- Distinct visibility in oncological imaging
How Tensive grows
Growth Strategy
Complete clinical validation and CE marking, scale manufacturing, launch in Europe and prepare for US market entry.
Distribution Model
Specialist sales to hospitals and surgeons, potentially supported by distribution partners in approved markets.
Moat (Defensibility)
Biomaterials patents, manufacturing know-how, clinical data, regulatory progress and integration into the surgical workflow.
Regulatory Context
REGENERA is a medical device under development. The company is pursuing CE marking and later US approval; it is not yet commercially available.
Key Risks
- Regulatory approval has not yet been obtained
- Clinical outcomes still require confirmation at scale and over longer follow-up
- Biomaterial manufacturing and quality-control challenges
- Surgeon adoption and healthcare reimbursement
- Conditions attached to the drawdown of the EIB tranches
Strategic Insights
- Public venture debt can extend a medtech company's runway without immediately increasing equity dilution.
- In medtech, the transition from promising clinical data to manufacturing and hospital adoption is a central part of the risk.
Funding & Investors
Funding Rounds
- 2025 - Series A: €14M
Lead: Panakès Partners - 2026 - Convertible venture debt: up to €20M
Lead: European Investment Bank
Key Investors
Founding Team
Founders
Key Executives
- Sanjay Kakkar - CEO
- Alberto Cantaluppi - Chief Medical Officer
- Valentina Morigi - Chief Financial Officer
Key Metrics
Lessons from Tensive
- Regulatory financing must cover industrialisation and market access as well as clinical trials.
- Product claims must remain proportionate to regulatory status and available evidence.
Similar Startups
HALE S.R.L. - SOCIETA' BENEFIT
Customized gynecology services with online specialist consultations and comprehensive women's health solutions.
Read AnalysisNOUS S.R.L.
Foodtech startup developing innovative ingredients for the Food & Beverage and nutraceutical markets.
Read Analysis1DIAGNOSIS S.R.L.
Medical diagnostics startup developing solutions to streamline and accelerate clinical diagnosis through technology.
Read AnalysisSources
- EIB backs Italian medtech Tensive with up to €20 million to advance breast reconstruction innovation — European Investment Bank
- Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant — Tensive
- Breast implant alternative startup Tensive receives €20 million EIB loan to advance REGENERA — EU-Startups
- Tensive raises €14,000,000 Series A Financing Round — Tensive
- About Tensive — Tensive